Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 14 |
| List of Tables | 13 | 2 |
| List of Figures | 15 | 1 |
| Introduction | 16 | 1 |
| Global Markets Direct Report Coverage | 16 | 1 |
| Wet (Neovascular / Exudative) Macular Degeneration Overview | 17 | 1 |
| Therapeutics Development | 18 | 1 |
| Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration Overview | 18 | 1 |
| Wet (Neovascular / Exudative) Macular Degeneration Therapeutics under Development by Companies | 19 | 4 |
| Wet (Neovascular / Exudative) Macular Degeneration Pipeline Products Glance | 23 | 3 |
| Late Stage Products | 23 | 1 |
| Clinical Stage Products | 24 | 1 |
| Early Stage Products | 25 | 1 |
| Wet (Neovascular / Exudative) Macular Degeneration Products under Development by Companies | 26 | 6 |
| Wet (Neovascular / Exudative) Macular Degeneration Companies Involved in Therapeutics Development | 32 | 51 |
| Aciont Inc. | 32 | 1 |
| Adverum Biotechnologies, Inc. | 33 | 1 |
| Allergan Plc | 34 | 1 |
| Alteogen Inc. | 35 | 1 |
| Amakem NV | 36 | 1 |
| Ampio Pharmaceuticals, Inc. | 37 | 1 |
| Apellis Pharmaceuticals, Inc. | 38 | 1 |
| Apexigen, Inc. | 39 | 1 |
| Applied Genetic Technologies Corporation | 40 | 1 |
| Benitec Biopharma Limited | 41 | 1 |
| Boehringer Ingelheim GmbH | 42 | 1 |
| Cell Medica Limited | 43 | 1 |
| Charlesson LLC. | 44 | 1 |
| Cipla Ltd. | 45 | 1 |
| Clanotech AB | 46 | 1 |
| Clearside BioMedical, Inc. | 47 | 1 |
| Clonz Biotech Private Limited | 48 | 1 |
| Coherus BioSciences, Inc. | 49 | 1 |
| Daiichi Sankyo Company, Limited | 50 | 1 |
| Diffusion Pharmaceuticals Inc. | 51 | 1 |
| Eleven Biotherapeutics Inc. | 52 | 1 |
| Exonate Limited | 53 | 1 |
| F. Hoffmann-La Roche Ltd. | 54 | 1 |
| Formycon AG | 55 | 1 |
| Graybug Vision Inc | 56 | 1 |
| GTx, Inc. | 57 | 1 |
| iCo Therapeutics Inc. | 58 | 1 |
| Icon Bioscience, Inc. | 59 | 1 |
| Iconic Therapeutics, Inc. | 60 | 1 |
| Kala Pharmaceuticals, Inc. | 61 | 1 |
| Kodiak Sciences Inc. | 62 | 1 |
| Mabion SA | 63 | 1 |
| MeiraGTx Limited | 64 | 1 |
| Mitotech S.A. | 65 | 1 |
| Ocular Therapeutix, Inc. | 66 | 1 |
| Ohr Pharmaceutical Inc. | 67 | 1 |
| Ophthotech Corp. | 68 | 1 |
| Oxford BioMedica Plc | 69 | 1 |
| PanOptica, Inc. | 70 | 1 |
| Pfenex Inc. | 71 | 1 |
| Pfizer Inc. | 72 | 1 |
| pSivida Corp. | 73 | 1 |
| Regeneron Pharmaceuticals Inc | 74 | 1 |
| RegenxBio Inc. | 75 | 1 |
| RXi Pharmaceuticals Corporation | 76 | 1 |
| Santen Pharmaceutical Co., Ltd. | 77 | 1 |
| Sanwa Kagaku Kenkyusho Co., Ltd. | 78 | 1 |
| TRACON Pharmaceuticals, Inc. | 79 | 1 |
| TWi Pharmaceuticals, Inc. | 80 | 1 |
| Tyrogenex, Inc. | 81 | 1 |
| Xbrane Biopharma AB | 82 | 1 |
| Wet (Neovascular / Exudative) Macular Degeneration Therapeutics Assessment | 83 | 13 |
| Assessment by Monotherapy Products | 83 | 1 |
| Assessment by Combination Products | 84 | 1 |
| Assessment by Target | 85 | 3 |
| Assessment by Mechanism of Action | 88 | 4 |
| Assessment by Route of Administration | 92 | 2 |
| Assessment by Molecule Type | 94 | 2 |
| Drug Profiles | 96 | 155 |
| (aflibercept + nesvacumab) Drug Profile | 96 | 1 |
| (aflibercept + rinucumab) Drug Profile | 97 | 1 |
| A-006 Drug Profile | 98 | 1 |
| abicipar pegol Drug Profile | 99 | 3 |
| AC-301 Drug Profile | 102 | 1 |
| ACX-107 Drug Profile | 103 | 1 |
| aflibercept Drug Profile | 104 | 9 |
| aflibercept biosimilar Drug Profile | 113 | 1 |
| aflibercept biosimilar Drug Profile | 114 | 1 |
| AGN-151200 Drug Profile | 115 | 2 |
| ALG-1001 Drug Profile | 117 | 3 |
| AMA-0428 Drug Profile | 120 | 1 |
| APL-2 Drug Profile | 121 | 2 |
| APX-003 Drug Profile | 123 | 1 |
| APX-3330 Drug Profile | 124 | 2 |
| AVA-101 Drug Profile | 126 | 3 |
| AVA-201 Drug Profile | 129 | 1 |
| avacincaptad pegol sodium Drug Profile | 130 | 2 |
| axitinib Drug Profile | 132 | 2 |
| AXT-108 Drug Profile | 134 | 1 |
| bertilimumab Drug Profile | 135 | 4 |
| Beta-LGND2 Drug Profile | 139 | 2 |
| BI-144807 Drug Profile | 141 | 1 |
| brolucizumab Drug Profile | 142 | 2 |
| C-16Y Drug Profile | 144 | 1 |
| CBT-128 Drug Profile | 145 | 1 |
| CLT-005 Drug Profile | 146 | 1 |
| CLT-28643 Drug Profile | 147 | 1 |
| cyclosporine Drug Profile | 148 | 1 |
| DA-3131 Drug Profile | 149 | 1 |
| danazol Drug Profile | 150 | 4 |
| DE-120 Drug Profile | 154 | 1 |
| DNX-214 Drug Profile | 155 | 1 |
| Doxarubicin Pegylated Drug Profile | 156 | 1 |
| Drug for Age Related Macular Degeneration Drug Profile | 157 | 1 |
| DS-7080 Drug Profile | 158 | 1 |
| ENV-1305 Drug Profile | 159 | 1 |
| GB-101 Drug Profile | 160 | 1 |
| Gene Therapy 1 for Wet Age-Related Macular Degeneration Drug Profile | 161 | 1 |
| Gene Therapy for Wet Age-related Macular Degeneration Drug Profile | 162 | 1 |
| hI-con1 Drug Profile | 163 | 2 |
| IVMED-50 Drug Profile | 165 | 1 |
| IVMED-55 Drug Profile | 166 | 1 |
| K-106 Drug Profile | 167 | 1 |
| KSI-201 Drug Profile | 168 | 1 |
| LHA-510 Drug Profile | 169 | 1 |
| Monoclonal Antibody to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile | 170 | 1 |
| OCU-200 Drug Profile | 171 | 1 |
| OLX-301 Drug Profile | 172 | 1 |
| ONL-1204 Drug Profile | 173 | 1 |
| OPT-302 Drug Profile | 174 | 4 |
| OXB-201 Drug Profile | 178 | 2 |
| PAN-90806 Drug Profile | 180 | 2 |
| pegpleranib sodium Drug Profile | 182 | 3 |
| PF-05206388 Drug Profile | 185 | 2 |
| PF-655 Drug Profile | 187 | 2 |
| plastoquinone decyl triphenylphosphonium bromide Drug Profile | 189 | 2 |
| Protein to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile | 191 | 1 |
| ranibizumab Drug Profile | 192 | 6 |
| ranibizumab biosimilar Drug Profile | 198 | 1 |
| ranibizumab biosimilar Drug Profile | 199 | 1 |
| ranibizumab biosimilar Drug Profile | 200 | 2 |
| ranibizumab biosimilar Drug Profile | 202 | 1 |
| ranibizumab biosimilar Drug Profile | 203 | 1 |
| ranibizumab biosimilar Drug Profile | 204 | 1 |
| ranibizumab biosimilar Drug Profile | 205 | 1 |
| Recombinant Protein for Age Related Macular Degeneration Drug Profile | 206 | 1 |
| Recombinant Proteins to Inhibit VEGF for Wet Age Related Macular Degeneration Drug Profile | 207 | 1 |
| RES-529 Drug Profile | 208 | 4 |
| RG-7716 Drug Profile | 212 | 1 |
| RGX-314 Drug Profile | 213 | 2 |
| RXI-109 Drug Profile | 215 | 6 |
| SK-1011 Drug Profile | 221 | 1 |
| Small Molecule for Wet AMD and Dry AMD Drug Profile | 222 | 1 |
| Small Molecules for Dry and Wet Age Related Macular Degeneration Drug Profile | 223 | 1 |
| Small Molecules to Inhibit SRPK-1 for Wet Macular Degeneration Drug Profile | 224 | 1 |
| SPHINX-31 Drug Profile | 225 | 1 |
| squalamine lactate Drug Profile | 226 | 8 |
| sunitinib malate Drug Profile | 234 | 2 |
| Synthetic Peptides to Inhibit VEGF for Wet Adult Macular Degeneration Drug Profile | 236 | 1 |
| TRC-105 Drug Profile | 237 | 8 |
| triamcinolone acetonide Drug Profile | 245 | 1 |
| TT-211 Drug Profile | 246 | 1 |
| TT-231 Drug Profile | 247 | 1 |
| X-82 Drug Profile | 248 | 3 |
| Wet (Neovascular / Exudative) Macular Degeneration Dormant Projects | 251 | 4 |
| Wet (Neovascular / Exudative) Macular Degeneration Discontinued Products | 255 | 1 |
| Wet (Neovascular / Exudative) Macular Degeneration Product Development Milestones | 256 | 10 |
| Featured News &Press Releases | 256 | 1 |
| Jul 25, 2016: Opthea Reports Positive Data From Wet AMD Clinical Trial | 256 | 1 |
| Jul 25, 2016: Opthea to Host Conference Call Providing Update on Phase 1 Wet AMD Clinical Trial With OPT-302 | 257 | 1 |
| Jul 07, 2016: Adverum Biotechnologies Provides wet AMD Program Update | 258 | 1 |
| Jun 20, 2016: Ophthotech Completes Patient Recruitment in Phase 3 Trial of Fovista Anti-PDGF Therapy in Combination with Eylea or Avastin in Wet Age-Related Macular Degeneration | 258 | 1 |
| Jun 07, 2016: Xbrane Biopharma Initiates Scale-Up of Production of its Ranibizumab Biosimilar Xlucane Ahead of Plan | 259 | 1 |
| May 25, 2016: Regeneron Announces Important US Prescribing Information Clarification for EYLEA (aflibercept) Injection | 259 | 1 |
| May 05, 2016: Opthea Doses First Patient in Phase 2A Dose Expansion Study for OPT-302 in Wet AMD | 260 | 1 |
| May 04, 2016: Graybug Vision GB-102 Toxicology/PK Study Presented at ARVO 2016 | 260 | 1 |
| May 02, 2016: Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee | 261 | 1 |
| May 02, 2016: Graybug Vision Collaborator Dr. Peter Campochiaro Presented at ARVO 2016 | 262 | 1 |
| Apr 27, 2016: Ohr Pharmaceutical Announces Presentation on Squalamine Lactate at the 2016 Association for Research in Vision and Ophthalmology Conference in Seattle, WA | 263 | 1 |
| Apr 25, 2016: Ophthalmology Product Company Graybug Vision to Present Data at ARVO 2016 | 263 | 1 |
| Apr 21, 2016: Opthea Phase 1 Wet AMD Clinical Trial With OPT-302 Meets Primary Safety Objective | 264 | 1 |
| Apr 18, 2016: Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program | 264 | 1 |
| Mar 30, 2016: Opthea Completes Patient Enrolment for OPT - 302 Phase 1 Dose Escalation Trial in Patients with Wet AMD | 265 | 1 |
| Appendix | 266 | 2 |
| Methodology | 266 | 1 |
| Coverage | 266 | 1 |
| Secondary Research | 266 | 1 |
| Primary Research | 266 | 1 |
| Expert Panel Validation | 266 | 1 |
| Contact Us | 266 | 1 |
| Disclaimer | 267 | 1 |